BioCardiaBCDA
BCDA
About: BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Employees: 20
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
44% more funds holding
Funds holding: 9 [Q3] → 13 (+4) [Q4]
0.17% less ownership
Funds ownership: 2.9% [Q3] → 2.73% (-0.17%) [Q4]
14% less capital invested
Capital invested by funds: $317K [Q3] → $272K (-$44.4K) [Q4]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$25
884%
upside
Avg. target
$25
884%
upside
High target
$25
884%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 18% 1-year accuracy 72 / 409 met price target | 884%upside $25 | Buy Reiterated | 18 Dec 2024 |
Financial journalist opinion
Based on 3 articles about BCDA published over the past 30 days
Neutral
GlobeNewsWire
22 hours ago
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System
SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office has granted Japanese Patent No. 7641330 titled “Radial and Transendocardial Delivery Catheter” with a patent term that will expire on or after September 30, 2034.
Neutral
GlobeNewsWire
1 week ago
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions
SUNNYVALE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the completion of source data verification and freezing of primary outcomes data in the double-blind randomized placebo-controlled Phase 3 CardiAMP HF study of its autologous minimally invasive cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF). Data from the 115 randomized patients in the study has been transferred to the Statistical Data Analysis Center core laboratory for analysis. Results are scheduled to be presented at the Late-Breaking Clinical Trials symposium at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago on March 30, 2025.
Neutral
GlobeNewsWire
3 weeks ago
BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)
Focus on Patients with Elevated Markers of Heart Stress and Inflammation Procedural enhancement using FDA Approved Morph DNA steerable guide for therapeutic delivery SUNNYVALE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today completion of enrollment and dosing in the low dose cohort in its CardiALLO™ Allogeneic Mesenchymal Cell Therapy Phase I/II trial.
Neutral
GlobeNewsWire
1 month ago
BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions
SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have been accepted for presentation in a late-breaking symposium at the American College of Cardiology 2025 Scientific Sessions, taking place in Chicago, March 29-31, 2025.
Neutral
GlobeNewsWire
3 months ago
BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure
SUNNYVALE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the successful completion of a consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on the next steps for the submission for registration of its lead therapeutic asset, BCDA-01, for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF).
Neutral
Seeking Alpha
3 months ago
BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript
BioCardia, Inc. (NASDAQ:BCDA ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kumar Raja - Brookline Capital Markets Operator Good afternoon, ladies and gentlemen.
Neutral
GlobeNewsWire
5 months ago
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market's Listing Requirements as required by the Hearing Panel's (the “Panel”) decision on May 13, 2024.
Neutral
GlobeNewsWire
6 months ago
BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the closing of its upsized public offering with participation from management and directors, institutional investors, and certain existing investors of the Company for the purchase and sale of 2,400,000 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,400,000 shares of common stock at a combined offering price of $3.00 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The company received aggregate gross proceeds of $7.2 million, before deducting placement agent fees and other offering expenses. The warrants have an exercise price of $3.00 per share, will be exercisable immediately and will expire five years from the issuance date.
Neutral
GlobeNewsWire
6 months ago
BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Food and Drug Administration (FDA) has cleared BioCardia to market the Morph DNA Steerable Introducer product family, subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act.
Neutral
GlobeNewsWire
6 months ago
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
BioCardia announced today that the FDA has approved an important protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3 trial
Charts implemented using Lightweight Charts™